16/10/2014 08:42:21

EXINI to arrange Bone Scan Index (BSI) symposium at important annual European congress

Lund, Sweden, 2014-10-16 09:42 CEST (GLOBE NEWSWIRE) --

EXINI and FUJIFILM RI Pharma will arrange a Bone Scan Index (BSI) symposium on

October 20th at this year’s EANM-congress (European Association of Nuclear

Medicine) held in Gothenburg, October 18-22.

The symposium called ”Bone Scan Index (BSI) A Nuclear Medicine Biomarker in

Metastatic Prostate Cancer”, commence at 13.00 p.m. For more information >>


”The symposium provide a unique opportunity for invited physicians within

nuclear medicine, to learn more about the imaging biomarker BSI and its

clinical applications. Arranging it together with our partner FUJIFILM RI

Pharma adds extensive clinical experience and insights gained from the success

of our product EXINI boneBSI (Bonenavi) on the Japanese market ”, comments

Magnus Aurell, CEO, EXINI Diagnostics AB.

Throughout the congress, several academic studies based upon use of the

software EXINI boneBSI and its BSI-calculating capacity, will be presented:

OP365: Prognostic value of bone scan index for treatment response and survival

in patients with high-risk prostate cancer. M. Reza, A. Bjartell, M. Ohlsson,

R. Kaboteh, P. Wollmer, L. Edenbrandt, E. Trägård

P491: Analytical validation of automated bone scan index as a candidate imaging

biomarker for advanced prostate cancer. A. Anand, L. Edenbrandt, A. Bjartell,

D. Minarik

P502: Reproducibility of automated bone scan index in patients with advanced

prostate cancer. A. Anand, L. Båth, R. Kaboteh, A. Bjartell, L. Edenbrandt

P786: Routine usefulness analysis of computer assisted diagnosis (CAD) software

for bone scan index L. Ferrer, M. Colombie, D. Rusu, D. Goulon, B. Jamet, N.

Varmenot, F. Kraeber-Bodere, C. Rousseau

More on Bone Scan Index (BSI):

BSI is an imaging biomarker providing fast, accurate and quantifiable

information to be used for diagnosis and stratification and the monitoring of

treatment response. It also provides increased accuracy in prognoses involving

patients suffering from skeletal metastases originating from prostate- or

breast cancer.

What is more, BSI has demonstrated its importance in the process of developing

new drugs, thus proving itself just as important for clinical use as for the

pharmaceutical industry. EXINI boneBSI is the only software capable of

extracting BSI-values for both these purposes.



For more information, please contact:

Magnus Aurell, CEO

Phone: +46 46 286 54 25

E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision

support to hospitals worldwide. The system is based on advanced image analysis

by artificial intelligence and can make its own interpretation of medical

images and provide diagnostic suggestions. In this way the system is used as a

decision support for the diagnosing doctor. EXINI is working with products for

the diagnosis of some of the most frequent endemic diseases such as cancer,

coronary heart disease, dementia and Parkinson's disease. The company was

founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock

market NASDAQ OMX First North and has about 600 shareholders. Principal owner

is Bo Håkansson. Consensus acts as Certified Adviser.


EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70

Lund, Sweden

Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com,


Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
20 Oct
Der er for tiden en del debat omkring øget prispres på vindmøllemarkedet - bl.a. som følge af at Sie..
20 Oct
  Jeg har gentagne gange analyseret Pandora. Læsere, som ønsker min analyse af Pandoras forretningsm..
18 Oct
Til direktionen.     Se så at få fyret den uduelige person, som I har ansat som moderator. Vedkommen..
18 Oct
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee votes 16 - 0 in favor of approval fo..
20 Oct
Jeg deler spekulationerne omkring Kåres tiltrædelse dvs. den dårlige nyhedsstrøm er snart slut. Min ..
18 Oct
Og til Moderator:     Du UNDERSTÅR dig i at fjerne dette indlæg uden at have forelagt det direktione..
18 Oct
Markedsværdi = DKK 64 milliarder   Pandora ejer 2,30 % af aktierne (som vi må antage ikke kommer i o..
16 Oct
Jeg har fuldstændig mistet enhver form for respekt for EU.   EU er i den grad blevet til en taberfor..
20 Oct
lugte af noget personligt mod alfinvest, vil jeg nu tillade mig at drage tvivl, både ved hans hensig..
20 Oct
Vanvittigt godt formuleret Peter. Det er næsten som at tage på universitetet og studere grønlandsk a..

Alliance Trust PLC : Net Asset Value(s)

23/10/2017 13:14:06
ALLIANCE TRUST PLC                                    At the close of business on Friday 20 October 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 778.5p -       including income, 787.1p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inco..

Rathbones : Form 8.3 - [Clinigen Group PLC]

23/10/2017 10:58:08
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Rathbone Brothers PLC (b) Owner or controller of ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
H.B. Fuller Poised for Global Growth with Acquisition of Royal Adhesives & Sealants
Sequent Announces Two New Sequent Platform Versions
Simmons Reports Third Quarter 2017 Earnings
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
MEDIA ADVISORY: US Commerce Secretary Wilbur Ross to Hold Listening Session at National Minority Supplier Development Council Annual Conference

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
23 October 2017 18:06:22
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171023.1 - EUROWEB7 - 2017-10-23 19:06:22 - 2017-10-23 18:06:22 - 1000 - Website: OKAY